Independent Valuation: Supporting Transaction, Impairment and IPO Decisions

Independent valuation is a decision-support discipline, not a search for a single universal "true value". Transaction work may assess a negotiated price or an investment value; financial reporting applies the measurement basis required by the relevant accounting standard; IPO valuation and disclosure are subject to listing requirements. The purpose, basis, valuation date and intended users should be explicit from the outset.[1][2][6]

Fair Value Under IFRS/HKFRS 13

IFRS/HKFRS 13 defines fair value as a market-participant exit price in an orderly transaction at the measurement date. It is a market-based, not entity-specific, measurement. IFRS 13 explains how to measure fair value when another standard requires or permits it; it does not itself require additional fair-value measurements.[2]

Technique selection should fit the asset and the available evidence. IFRS 13 requires valuation techniques to maximise relevant observable inputs and minimise unobservable inputs. The fair-value hierarchy gives the highest priority to Level 1 inputs and the lowest priority to Level 3 inputs.[2][3]

Intangible Assets and the Income Approach

Intangible valuation depends on identifiable economic benefits and defensible assumptions. Common examples include patents, brands, customer data, software, licences and marketing rights. Ascent Partners' article notes that the income approach, including discounted cash flow, is commonly used where asset-specific future benefits can be estimated; comparable transactions may also inform the analysis.[1]

For financial reporting, the accounting question comes before the valuation method. IFRS 13 applies when fair value is required or permitted by another IFRS; it does not replace the recognition and measurement requirements of standards such as IFRS 3 or IAS 36. The valuation must therefore be scoped to the relevant accounting purpose.[2]

Impairment Testing Is Not Fair-Value Measurement

Impairment testing is not interchangeable with fair-value measurement. IAS 36's impairment framework compares an asset's carrying amount with recoverable amount; the latter is based on value in use and fair value less costs of disposal. The available search results do not include the official IAS 36 text, so this point should be checked against the applicable HKAS 36/IAS 36 wording before publication.

IVS and Professional Standards

IVS has a current edition effective for valuations performed from 31 January 2025. It includes general requirements applicable across valuations and asset standards including IVS 200 for businesses and business interests and IVS 210 for intangible assets. IVS compliance requires following the general standards, applicable asset standards and appendices.[6]

An independent valuation can support transaction diligence and decision-making, but it does not replace governance or audit work. The Ascent article describes valuation as a tool for assessing trade prices, due diligence and strategic planning; the report's assumptions, evidence and limitations still need review by the relevant decision-makers and assurance professionals.[1]

IPO Disclosure Expectations

IPO disclosure should make the valuation understandable and testable. In HKEX guidance on biological assets, the Exchange calls for disclosure of the valuer's qualifications and independence, methods and reasons for selection, material assumptions and inputs, and sensitivity analysis; it also expects sponsor due diligence and independent qualified valuation absent cogent reasons.[3]

That IPO guidance is asset-specific, not a blanket rule for every valuation report. The cited HKEX letter concerns biological assets. A separate HKEX guidance letter for listing applications calls for valuation reports, where relevant, to explain methods, key assumptions, expert qualifications and material findings, and sets a timing expectation for the effective valuation date in its stated context.[3][4]

HKEX's cited biological-asset guidance refers to a Main Board profit test of HK$20 million for the most recent year and HK$30 million in aggregate for the preceding two years; these are figures in that specific guidance context, not general valuation thresholds.[3]

Sustainability-Related Information

Sustainability-related information can create valuation questions, but the available sources do not establish a specific new valuation rule. For a publishable discussion, distinguish valuation inputs—such as forecasts, risks and cash flows—from sustainability disclosure requirements, and verify any claims about current Hong Kong sustainability standards against primary HKEX/HKICPA material.

Conclusion

Independent valuation underpins transaction, impairment and IPO decisions by aligning purpose, basis and evidence with the applicable standards. Whether under IFRS/HKFRS 13, IAS 36 or IVS, the discipline lies in scoping the engagement correctly, selecting techniques that fit the asset, and ensuring disclosure is transparent and reviewable.[1][2][6]